Logo
    Search

    291. Evolution, Accelerated

    en-usJune 15, 2017

    Podcast Summary

    • The power of curiosity-driven researchCuriosity-driven research can lead to groundbreaking discoveries, like Jennifer Doudna's discovery of CRISPR for genetic editing.

      Curiosity-driven research can lead to groundbreaking discoveries, as demonstrated by the story of Jennifer Doudna's discovery of CRISPR. At the time, Doudna was a professor with a long-standing interest in understanding genetic control and evolution. When she first heard the term CRISPR in 2006, she had no idea what it was. It was a puzzle that grew to consume her for years. The bacteria that grow in toxic environments had developed a pattern-based immune system to protect themselves, and Doudna, along with Jill Banfield, set out to understand how it worked. What they discovered was a gene editing tool that has already begun changing medicine and has the potential for boundless change. The technology for genetic editing through CRISPR is here now, and Doudna's work is a testament to the importance of following one's curiosity and the potential for accidental discoveries to revolutionize science.

    • Revolutionizing Gene Editing with CRISPR-Cas9The discovery of CRISPR-Cas9 system revolutionized gene editing technology, with potential applications in eradicating diseases and providing new level of control in human manipulation of evolution.

      Jennifer Doudna and Emmanuel Charpentier's discovery of the CRISPR-Cas9 system revolutionized gene editing technology. This bacterial immune system, which can precisely cut DNA, was transformed into a powerful tool for scientific research. The implications are vast, with potential applications in eradicating diseases like cystic fibrosis, muscular dystrophy, HIV, and even cancer. Doudna, a scientist with a humble background, was thrust into the spotlight as a scientific superhero after the publication of their research in the journal Science. The technology, which allows for specific changes to be made to DNA, represents a new level of control in human manipulation of evolution. Doudna and her colleague Samuel Sternberg explore the ethical and philosophical implications of this breakthrough in their book "A Crack in Creation."

    • Revolutionizing Plant Breeding with CRISPR-Cas9CRISPR-Cas9 technology enables precise DNA editing, revolutionizing plant breeding by allowing for beneficial changes without unintended consequences, but may require new regulations and public education due to potential controversy

      CRISPR-Cas9 technology allows scientists to edit DNA by tapping into a cell's natural repair mechanism. This precision editing has the potential to revolutionize various fields, including agriculture. In the past, plant breeding relied on introducing genetic changes through chemicals or radiation, resulting in unintended consequences. CRISPR-Cas9 offers the opportunity to make precise changes, benefiting plants by giving them the ability to grow in adverse conditions and defend against pests. However, the use of gene editing in agriculture may raise concerns, as the term "genetically modified organisms" can be controversial. Despite the long history of genetic modification in plants, the precision and control offered by CRISPR-Cas9 may require new regulations and public education to address any potential concerns.

    • Exploring the societal implications of CRISPR gene editingCRISPR gene editing holds immense potential in agriculture, animal breeding, and social sciences, but ethical concerns arise as we navigate the technological and societal shifts, requiring careful regulation.

      The CRISPR gene editing technology is revolutionizing various fields, including agriculture, animal breeding, and even social sciences. The potential benefits are vast, from creating food crops better adapted to specific environments to producing animals with improved nutritional value or desirable traits. However, as the technology advances, ethical concerns arise, such as the potential misuse of gene editing in humans and animals. The social genomics revolution, which explores the societal implications of genetic research, is also gaining momentum. Sociologist Dalton Conley's book, "The Genome Factor," discusses the social genomics revolution and its impact on our understanding of identity, history, and the future. As we navigate these technological and societal shifts, it's crucial to consider the ethical implications and regulate these advancements appropriately.

    • Understanding complex diseases and traits through geneticsGenetics is moving beyond a focus on a few key genes to consider the collective impact of hundreds or thousands of genes on complex traits and diseases, using polygenic scores.

      The field of genetics and its application to understanding human diseases and traits has seen a significant shift with the availability of cheap genetic data. The human genome, which was once thought to hold a few key genes controlling diseases or traits, is now understood to be more complex, with hundreds or thousands of genes each having tiny effects. This complexity is being addressed through the use of polygenic scores, which summarize the collective impact of multiple genes on a particular trait or disease. However, the current predictive power of these scores is limited, and their use by external authorities and companies raises ethical concerns. The revolution in genetics is still in its early stages, but it holds great promise for understanding and addressing complex diseases and traits.

    • Ethical concerns of genetic information in the marriage marketGenetic technology raises ethical concerns, particularly in marriage market context, and could resemble past eugenics movements. It's essential to proceed responsibly and engage stakeholders to prevent past mistakes.

      The availability of genetic information through technology raises significant ethical concerns, particularly in the context of the marriage market and potential misuse of the information for discriminatory purposes. This technology, while new, has the potential to resemble past eugenics movements that led to devastating consequences. It is crucial that we proceed responsibly and engage in meaningful discussions involving various stakeholders to prevent a repeat of history and ensure the ethical use of this technology. The existence of a suitable mechanism or forum for such discussions is an ongoing question, but efforts are being made to bring people together for productive conversations.

    • Navigating Ethical Questions of CRISPR Gene-EditingThe ethical implications of CRISPR gene-editing extend beyond academia, requiring effective communication and robust governance to ensure safety, effectiveness, and equitable access. Distinguishing germline from somatic editing and considering the potential impact on future generations is crucial.

      The CRISPR gene-editing technology, with its potential to reshape human beings, raises profound ethical questions that go beyond the realm of academia. Effective communication through various mediums, including media, science fiction, movies, music, and visual arts, will be crucial in understanding and navigating these complex issues. The distinction between germline and somatic editing is significant, as changes to the germline can be inherited and have far-reaching implications for human evolution. The potential for this technology to impact not just individuals but future generations requires careful consideration and robust governance to ensure safety, effectiveness, and equitable access. The comparison to geoengineering highlights the importance of addressing the ethical and practical implications of this technology before widespread deployment.

    • Exploring CRISPR-Cas9's potential in human health and genetic researchCRISPR-Cas9 technology holds immense potential for positive advancements in human health and genetic research, but requires collaboration, understanding, and ethical considerations to ensure accessibility and proper use.

      CRISPR-Cas9 technology, while raising valid concerns about ethics, scarcity, and societal implications, holds immense potential for positive advancements in human health and genetic research. It's crucial for scientists, regulators, and thought leaders to collaborate in understanding the science behind this technology and ensuring its benefits reach communities worldwide. The prospect of extended lifespan is intriguing, but only if those extra years are high-quality and productive. The uncertainty surrounding patent rights and the distribution of proceeds from these discoveries adds another layer of complexity to the discussion. Ultimately, the goal should be to harness the power of CRISPR-Cas9 for the betterment of humanity, ensuring accessibility and ethical use.

    • Koch's Involvement in Politics and Perspective on SocietyBillionaire businessman Charles Koch believes in societal reform and reducing elite power, but acknowledges uncertainty and contradicts being just a 'nerd' despite controversial politics, engaging in public discourse through Freakonomics Radio.

      Charles Koch, the chairman and CEO of Koch Industries and one half of the Koch brothers, is a billionaire businessman who has become involved in the political arena despite knowing it would be unpleasant and sometimes dishonest. He has a strong belief in reforming society and reducing the influence of royalty or elite power, but acknowledges the uncertainty of whether such changes would be effective. Koch also emphasizes that he is not just a businessman, but a fun-loving person, contradicting the common perception of him as a "nerd." Despite his involvement in controversial politics, Koch continues to engage in public discourse to share his perspective on various issues. Freakonomics Radio, a podcast that interviewed Koch, is produced by WNYC Studios and Dubner Productions, and can be subscribed to on various platforms or accessed on their website for transcripts and research links.

    Recent Episodes from Freakonomics Radio

    594. Your Brand’s Spokesperson Just Got Arrested — Now What?

    594. Your Brand’s Spokesperson Just Got Arrested — Now What?

    It’s hard to know whether the benefits of hiring a celebrity are worth the risk. We dig into one gruesome story of an endorsement gone wrong, and find a surprising result.

     

    • SOURCES:
      • John Cawley, professor of economics at Cornell University.
      • Elizabeth (Zab) Johnson, executive director and senior fellow with the Wharton Neuroscience Initiative at the University of Pennsylvania.
      • Alvin Roth, professor of economics at Stanford University.

     

     

    Freakonomics Radio
    en-usJune 27, 2024

    593. You Can Make a Killing, but Not a Living

    593. You Can Make a Killing, but Not a Living

    Broadway operates on a winner-take-most business model. A runaway hit like Stereophonic — which just won five Tony Awards — will create a few big winners. But even the stars of the show will have to go elsewhere to make real money. (Part two of a two-part series.)

     

     

     

    Freakonomics Radio
    en-usJune 20, 2024

    EXTRA: The Fascinatingly Mundane Secrets of the World’s Most Exclusive Nightclub

    EXTRA: The Fascinatingly Mundane Secrets of the World’s Most Exclusive Nightclub

    The Berlin dance mecca Berghain is known for its eight-hour line and inscrutable door policy. PJ Vogt, host of the podcast Search Engine, joins us to crack the code. It has to do with Cold War rivalries, German tax law, and one very talented bouncer.

     

    • SOURCES:
      • Lutz Leichsenring, executive board member of Clubcommission Berlin and co-founder of VibeLab.
      • PJ Vogt, reporter, writer, and host of the podcast Search Engine.

     

     

    Freakonomics Radio
    en-usJune 17, 2024

    592. How to Make the Coolest Show on Broadway

    592. How to Make the Coolest Show on Broadway

    Hit by Covid, runaway costs, and a zillion streams of competition, serious theater is in serious trouble. A new hit play called Stereophonic — the most Tony-nominated play in history — has something to say about that. We speak with the people who make it happen every night. (Part one of a two-part series.)

     

     

    Freakonomics Radio
    en-usJune 13, 2024

    591. Signs of Progress, One Year at a Time

    591. Signs of Progress, One Year at a Time

    Every December, a British man named Tom Whitwell publishes a list of 52 things he’s learned that year. These fascinating facts reveal the spectrum of human behavior, from fraud and hypocrisy to Whitwell’s steadfast belief in progress. Should we also believe?

     

     

    Freakonomics Radio
    en-usJune 06, 2024

    EXTRA: The Opioid Tragedy — How We Got Here

    EXTRA: The Opioid Tragedy — How We Got Here

    An update of our 2020 series, in which we spoke with physicians, researchers, and addicts about the root causes of the crisis — and the tension between abstinence and harm reduction.

     

    • SOURCES:
      • Gail D’Onofrio, professor and chair of emergency medicine at the Yale School of Medicine and chief of emergency services at Yale-New Haven Health.
      • Keith Humphreys, professor of psychiatry and behavioral sciences at Stanford University.
      • Stephen Loyd, chief medical officer of Cedar Recovery and chair of the Tennessee Opioid Abatement Council.
      • Nicole O’Donnell, certified recovery specialist at the University of Pennsylvania's Center for Addiction Medicine and Policy.
      • Jeanmarie Perrone, professor of emergency medicine at the University of Pennsylvania.
      • Eileen Richardson, restaurant manager.

     

     

    Freakonomics Radio
    en-usJune 03, 2024

    590. Can $55 Billion End the Opioid Epidemic?

    590. Can $55 Billion End the Opioid Epidemic?

    Thanks to legal settlements with drug makers and distributors, states have plenty of money to boost prevention and treatment. Will it work? (Part two of a two-part series.)

     

    • SOURCES:
      • Keith Humphreys, professor of psychiatry and behavioral sciences at Stanford University.
      • Stephen Loyd, chief medical officer of Cedar Recovery and chair of the Tennessee Opioid Abatement Council.
      • Christine Minhee, founder of OpioidSettlementTracker.com.

     

     

    Freakonomics Radio
    en-usMay 30, 2024

    589. Why Has the Opioid Crisis Lasted So Long?

    589. Why Has the Opioid Crisis Lasted So Long?

    Most epidemics flare up, do their damage, and fade away. This one has been raging for almost 30 years. To find out why, it’s time to ask some uncomfortable questions. (Part one of a two-part series.)

     

    • SOURCES:
      • David Cutler, professor of economics at Harvard University.
      • Travis Donahoe, professor of health policy and management at the University of Pittsburgh.
      • Keith Humphreys, professor of psychiatry and behavioral sciences at Stanford University.
      • Stephen Loyd, chief medical officer of Cedar Recovery and chair of the Tennessee Opioid Abatement Council.

     

     

    Freakonomics Radio
    en-usMay 23, 2024

    Extra: Car Colors & Storage Units

    Extra: Car Colors & Storage Units

    Presenting two stories from The Economics of Everyday Things: Why does it seem like every car is black, white, or gray these days? And: How self-storage took over America.

     

    • SOURCES:
      • Tom Crockett, classic car enthusiast.
      • Zachary Dickens, executive vice president and chief investment officer of Extra Space Storage.
      • Mark Gutjahr, global head of design at BASF.
      • Kara Kolodziej, self-storage unit tenant.
      • Anne Mari DeCoster, self-storage consultant.
      • Nikkie Riedel, carline planning manager at Subaru of America.

     

     

    Freakonomics Radio
    en-usMay 20, 2024

    588. Confessions of a Black Conservative

    588. Confessions of a Black Conservative

    The economist and social critic Glenn Loury has led a remarkably turbulent life, both professionally and personally. In a new memoir, he has chosen to reveal just about everything. Why?

     

    • SOURCE:
      • Glenn Loury, professor of economics at Brown University and host of The Glenn Show.

     

     

    Freakonomics Radio
    en-usMay 16, 2024

    Related Episodes

    What happens when human beings take control of their own evolution?

    What happens when human beings take control of their own evolution?
    Over the past decade, scientists have developed what was once just the subject of dystopian fiction: gene editing technology. It's known as CRISPR. Jennifer Doudna, a professor of molecular and cell biology and chemistry at the University of California Berkeley, was a key member of the research group that developed the technology. She's also the co-author of the recent book A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution. A straightforward description of CRISPR is mind-boggling in what it suggests. As Doudna writes, “the genome — an organism’s entire DNA content, including all its genes — has become almost as editable as a simple piece of text.” It is possible that when the history of this era is written, most of our obsessions — Trump, tax rates, cybersecurity, Obamacare, NFL protests — will be forgotten, and CRISPR will be where historians focus. With great power comes great responsibility — and genuine terror. Doudna had a nightmare as her lab and others started to use CRISPR to make heritable changes in genes. She dreamed that her colleague wanted her to meet someone interested in her research — and it was Adolf Hitler with a pig face, waiting to take notes on the technology she developed. She awoke from that dream in a cold sweat. And the concerns that dream represent pushed her to discuss the implications of CRISPR technology publicly. CRISPR could do enormous good or tremendous harm — or both. In this conversation, Doudna and I discuss its possibilities, its dangers, its technical obstacles, the regulatory questions it raises, and much more. Books: The Double Helix by Jim Watson Sapiens: A Brief History of Humankind by Yuval Noah Harari The Making of the Atomic Bomb by Richard Rhodes Learn more about your ad choices. Visit podcastchoices.com/adchoices

    Ep#012: Personalization in Reproductive Medicine in the Era of CRISPR/Cas9 with Dr. Helen O'Neill

    Ep#012: Personalization in Reproductive Medicine in the Era of CRISPR/Cas9 with Dr. Helen O'Neill
    In Episode 12, we discuss the progress of personalization in the field of reproductive medicine with our guest Dr. Helen O'Neill. Helen is a Lecturer in Reproductive and Molecular Genetics and Director for the MSc Program in Reproductive Science and Women’s Health at the Institute for Women’s Health, University College London. She has over 10 years of experience as a researcher and science communicator on various topics of reproductive medicine, genome editing, and women’s health. Beyond her work as an academic, she recently co-founded Hertility Health with the aim to change the face of women’s health.

    Our host Luisa talked to Helen about:

    ◦ The importance of reproductive health
    ◦ The power of genome editing
    ◦ CRISPR as a collection of technologies
    ◦ Ethical concerns around genome editing
    ◦ Using sequencing to examine embryo development
    ◦ Gene editing in clinical settings
    ◦ Start-up story of Hertility Health
    ◦ Why women's health research is still in its infancy
    ◦ The need for open science communication
    ◦ Including men in fertility education
    ◦ Launching a start-up during COVID-19
    ◦ Improving women's health through more research
    ◦ The future of personalized medicine in reproductive health

    Get in touch with Helen:
    UCL Iris profile: Helen O Neill
    Twitter: @DrHelenONeill
    LinkedIn: Dr Helen O' Neill
    Instagram @dr.helenoneill
    Web: https://hertilityhealth.com/

    Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

    George Scangos (Vir Biotechnology) - Making a Difference in Biotech

    George Scangos (Vir Biotechnology) - Making a Difference in Biotech

    As the president and CEO of Vir Biotechnology, as well as in his role as head of BIO’s Coronavirus Collaboration Initiative, George Scangos has emerged as a global leader in the fight against COVID-19. In this conversation with Stanford structural biology professor Jody Puglisi, Dr. Scangos explains the challenge of building financially viable therapies for infectious diseases, talks about the current status of COVID-related research, and explores how to build an innovative and meaningful career in biotech.

    SoT 319: Number Five Is Alive

    SoT 319: Number Five Is Alive

    Hosts: Ed Brown, Penny Dumsday, Lucas Randall, Jo Benhamu

    00:02:27 NASA's InSight probe lands on Mars, with a slew of instruments to analyse what the red planet is made of.

    00:17:43 Against all conventional knowledge, mitochondrial DNA is sometimes inherited from the father.

    00:28:01 Professor He Jiankui announced he's created the world's first ever gene edited babies using the CRISPR-Cas9 technique. His claims of HIV immune babies are extraordinary, but mired in contention amongst ethical and procedural controversy.

     

    Jo Benhamu is a Clinical Research Nurse with a Masters in Bioethics.

     

    This episode contains traces of Sir David Attenborough speaking at the COP24 UN conference in Katowice, Poland.